Loading
Life sciences · Journal article
Nature Communications · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Ras proteins regulate signaling pathways initiated by tyrosine kinase receptors, and activating Ras mutations are drivers in cancer and RASophaties. The development of therapies against these diseases requires a profound understanding of how Ras mutations modify pathway output and interact with other pathway components. Here we generated G12V activating mutations in the Drosophila Ras1 locus and used Ras1 G12V and human KRASB G12V to analyze in vivo the consequences of endogenous Ras G12V expression and its interplay with other components of the EGFR/MAPK pathway. We find that Ras G12V acts as an amplifier of EGFR stimulation. Consistently, Ras G12V proteins respond to EGFR and can compensate for EGFR loss to generate basal levels of ERK activity. However, full pathway activation by Ras G12V is strictly dependent on EGFR function. Altogether, our results suggest that EGFR not only activates wild type Ras, but also Ras G12V, and support the notion that Ras G12V mutants are non-constitutively active.